C
ervical arthroplasty has been shown in clinical studies to provide satisfying results in the treatment of degenerative cervical disc disease. Outcome measures have shown improvement in neck and arm pain that has equaled or surpassed results obtained with cervical fusion. 1 , 2 Compared with a more than 50-year experience with cervical fusion, experience with arthroplasty is limited. 3 Hence, the long-term outcome and complications remain unknown. 4 Results from large clinical trials of artifi cial cervical disc trials have been published. 5 , 6 Most clinical studies of spine fi xation for fusion include follow-up intervals of 2 to 4 years. Published reports of arthroplasty have included similar lengths of follow-up. However, devices that promote spine fusion may have different failure characteristics and occurrence intervals than arthroplasty. Extrapolating this follow-up interval to spinal arthroplasty may not capture complications occurring with a motion-preserving device. Very late complications such as implant failure, and wear debris-induced osteolysis, are well known in large joint arthroplasty. 7 , 8 Thus, an appropriate follow-up interval for spinal arthroplasty may extend beyond that typically applied to patients who undergo cervical fusion. This study examines delayed device-related complications that call into consideration the appropriate follow-up interval for patients who undergo cervical arthroplasty (CA).
MATERIALS AND METHODS
The corresponding author agreed to take part in a single-site Food and Drug Administration device study of the Bryan cervical disc prosthesis. The device is a metal-on-polymer design with titanium endplates and a core of polyurethane surrounded by a polyurethane shell. After obtaining investigational review board approval and undergoing procedure training on cadavers, we began enrolling patients in our randomized controlled study of the Bryan cervical disc prosthesis. Eligibility was limited to patients who failed conservative therapy with 1-level degenerative cervical disc disease causing radiculopathy and/or myelopathy with or without neck pain. Diagnostic studies included magnetic resonance imaging, and computed tomographic scanning, obtaining plain radiographs with dynamic anteropostero and lateral motion views. Loss of motion at the symptomatic level was a contraindication to the procedure.
All patients underwent anterior microdiscectomy with one-to-one randomization to Bryan CA or anterior cervical fusion (ACF). A total of 28 patients enrolled in the clinical trial received the Bryan disc. An additional 3 patients were included in continued access status without randomization, and 1 patient was granted compassionate use who did not meet study requirements because of a previous 2-level cervical fusion. None of these 4 patients returned with very late complications. Patient radiographs and clinical data were recorded preoperatively and scheduled postoperatively at 1, 6, 12, and 24 weeks and at 12, 24, 48, and 60 months.
The authors also participated in a Food and Drug Administration device study of the Prestige LP CA device. The Prestige LP device is a metal-on-metal design constructed of titanium-aluminum alloy (Ti-6Al-4V) with carbide dispersion. The study design and enrollment criteria were similar to the Bryan study. Nineteen patients received Prestige LP arthroplasty devices.
All study patients were told to return any time for complaints of neck or extremity symptoms. The authors defi ned very late complications as those occurring beyond 48 months from a surgical procedure in distinction to the designation of late complications applied to those occurring 24 months after a procedure.
RESULTS
Similar numbers of patients in the ACF and CA study groups presented with symptoms attributed to adjacent segment disease and were not studied further. Five patients in the arthroplasty groups presented with symptoms thought to be due to their device. Four of these patients had undergone Bryan CA, and 1 patient has a Prestige LP device. Of the 4 Bryan patients, 2 were beyond 4 and 2 others had past 5 years of follow-up. The Prestige LP patient was beyond 4 years of follow-up. Clinical data for these patients were similar to the entire clinical series in regard to preoperative symptoms, age, and cigarette smoking. Females accounted for 53 percent of our study population, whereas all 5 patients with late complications were females. Two Bryan patients underwent surgical revision. One patient had device subluxation with ventral cord effacement and subtle fi ndings of cervical myelopathy. Device removal was followed by cervical fusion. At the last follow-up, she rated her outcome as fair. The other Bryan revision involved marked loss of vertebral body bone with deformity ( Figure 1 ) . The patient noted recurrent neck and arm pain. Device explantation was followed by 2-level ACF ( Figure 2 ). She reported a good outcome at the last follow-up. Despite extensive tissue review by independent laboratories in all explantation cases, hers was the only 1 to show abnormal fi ndings. Evaluation of the tissue and bone samples adjacent to the device suggested the potential for a low virulence bacterial infection based on microscopic slides of macrophages. However, no pathological agent was identifi ed, and all cultures were negative.
The 2 other Bryan patients had symptoms of neck pain only. Haloing about their arthroplasty devices consistent with bone loss was identifi ed. They were observed only. One patient reported improvement, and follow-up fi lms 1 year later showed resolution of the haloing. lost to follow-up. Upon review of their earlier fi lms, subtle haloing could be seen as early as 6 months postoperatively in the patient who noted later improvement.
The Prestige LP patient noted neck and arm pain, and studies showed loss of vertebral body height, deformity, and heterotopic ossifi cation versus regrowth of an osteophyte compressing her right C6 nerve root in the neural foramen ( Figure 3 ). Device removal was followed by 2-level fusion. Improvement was minimal. Her fusion grafts subsided, causing marked kyphosis necessitating corpectomy and posterior fusion fi xation. She reported a fair outcome.
DISCUSSION
The purpose of this publication is to make surgeons aware that device-related complications may occur in a delayed fashion with CA. Surgeons who routinely perform and follow patients after cervical fusion must be cognizant that arthroplasty and cervical fusion are distinctly different procedures in regard to the occurrence of very late complications.
Preservation of the spinal motion segment is an attractive alternative to spine fusion. Benefi ts have been described such as a more rapid return to work and avoidance of bracing. 9 Yet, the trade-off for preserving motion is exposing patients to potential complications largely unknown in the cervical fusion population. Infection or device malfunction with loss of motion are obvious potential device-related complications. Less obvious may be a failure of "fusion" or osteointegration of the arthroplasty device into the adjacent verterbral bodies. This failure of a solid attachment may result in neck pain or device migration. A device with moving parts creates wear debris. This has been well documented in large joint arthroplasty and was confi rmed in the initial Bryan Disc bench top testing. 10 , 11 Device failure resulting from osteolysis with spine arthroplasty has been reported. van Ooij et al 
Key Points
CA and cervical fusion are di erent procedures in terms of very late complications. Spine arthroplasty exposes patients to complications similar to those seen in large joint arthroplasty.
The most appropriate follow-up interval for CA has not been de ned by recent clinical trials. Our study suggests that it extend signi cantly longer than that typically applied to patients who underwent cervical fusion.
The implants had been placed between 1.8 and 16 years earlier. They noted fracture and wear patterns in the polyethelene core that increased over time with surface damage similar to that described with hip and knee implants.
The cause of bone loss as it relates to the complications described in this article is unknown. No convincing evidence of osteolysis was seen. However, given the experience with lumbar devices, the potential for CA-related osteolysis must exist.
No treatment currently exists that restores the degenerative cervical spine to its normal state. Our surgical treatments all carry trade-offs of 1 sort or another. ACF sacrifi ces a motion segment but achieves satisfying results leaving behind only the patient's biology with, depending on the surgeon's preference, a fi xation plate. CA also achieves satisfying results and has the benefi t of preserving the motion segment. However, the patient who underwent arthroplasty from that point forward has a mechanical device residing in their neck. We know from implanted "moving parts" elsewhere in the body that they are generally safe but do not come with lifetime guarantees.
CONCLUSION
CA is a unique cervical spine surgical procedure. Longer follow-up intervals should be considered for these patients in comparison with those treated with cervical fusion. We recommend that patients treated with arthroplasty undergo lateral cervical spine radiography every 2 years. They should also be well informed about the potential for very late complications.
